Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Brain injury after spontaneous intracerebral hemorrhage results from pathophysiologic
responses in the brain parenchyma due to hematoma formation, release of clot components, and
surrounding edema. Inflammatory cascade activation in the perihematomal brain parenchyma has
been implicated in the pathogenesis of secondary brain injury. Statins have been identified
as a potential neuroprotective agent that targets the inflammatory response to intracerebral
hemorrhage. In preclinical studies, statin treatment in animal intracerebral hemorrhage
models has consistently demonstrated neuroprotective and recovery enhancement effects.
Clinical investigations in humans reported better patient outcomes associated with statin use
in patients with intracerebral hemorrhage, including reduced perihematomal edema, lower
mortality rates, and improved functional outcomes.